Literature DB >> 1916994

Endothelin in hypertensive resistance arteries. Intraluminal and extraluminal dysfunction.

Y Dohi1, T F Lüscher.   

Abstract

The effects of intraluminal and extraluminal endothelin-1 and its interactions with endothelium-derived relaxing factor were studied in perfused mesenteric resistance arteries of Wistar-Kyoto rats and spontaneously hypertensive rats. Changes in intraluminal diameter were recorded. In adult Wistar-Kyoto rats, but not spontaneously hypertensive rats, low concentrations of intraluminal endothelin-1 (10(-10) to 10(-9) M) caused relaxations of quiescent arteries blocked by indomethacin. After endothelial removal, intraluminal endothelin-1 evoked concentration-dependent contractions in both strains. Extraluminal endothelin-1 caused greater contractions of arteries with endothelium than intraluminal endothelin-1, and the sensitivity was lower in adult hypertensive rats; endothelial removal enhanced the contractions to extraluminal endothelin-1 to a greater extent in hypertensive than in normotensive rats. In arteries without endothelium, intraluminal and extraluminal endothelin-1 caused comparable contractions, but the sensitivity was reduced in adult but not young hypertensive as compared with normotensive rats. Both young spontaneously hypertensive and normotensive rats exhibited a high sensitivity to the peptide. In arteries precontracted with endothelin-1, endothelium-dependent relaxation to intraluminal acetylcholine was reduced in hypertensive as compared with normotensive rats, whereas relaxations to extraluminal acetylcholine were increased in hypertensive rats. Thus, endothelin-1 interacts with both vascular smooth muscle and the endothelium. The sensitivity of vascular smooth muscle to endothelin-1 is reduced in adult hypertensive rats. Intraluminal activation of the endothelium by endothelin-1 or acetylcholine is reduced in spontaneously hypertensive rats, whereas extraluminal activation causes more pronounced responses in hypertensive than in normotensive rats, suggesting a prominent dysfunction of the intraluminal surface of the endothelium in hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916994     DOI: 10.1161/01.hyp.18.4.543

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Higher circulatory level of endothelin-1 in hypertensive subjects screened through a cross-sectional study of rural Bangladeshi women.

Authors:  Shamima Akter; Subrina Jesmin; Yoshio Iwashima; Sakuramoto Hideaki; Md Arifur Rahman; Md Majedul Islam; Masao Moroi; Nobutake Shimojo; Naoto Yamaguchi; Takashi Miyauchi; Satoru Kawano; Taro Mizutani; Yuhei Kawano
Journal:  Hypertens Res       Date:  2014-11-13       Impact factor: 3.872

2.  Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients.

Authors:  A Gass; J Flammer; L Linder; S C Romerio; P Gasser; W E Haefeli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

Review 3.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 4.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Age-related changes in vascular smooth muscle and endothelium.

Authors:  Y Dohi; M Kojima; K Sato; T F Lüscher
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

Review 7.  Regulation of matrix proteins and impact on vascular structure.

Authors:  J Tuñón; M Ruiz-Ortega; J Egido
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

8.  Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1.

Authors:  W G Haynes; M F Hand; H A Johnstone; P L Padfield; D J Webb
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

9.  Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide.

Authors:  R R Wenzel; S Zbinden; G Noll; B Meier; T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 10.  Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.

Authors:  T F Lüscher; R R Wenzel; P Moreau; H Takase
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.